St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Drugs
- AdamTS4 inhibitor for respiratory infection (SJ-20-0025)
- Amylase or maltose to treat or prevent neurodegeneration (SJ-20-0009)
- BET Bromodomain inhibitors (SJ-16-0032)
- Biologically Active Ganoderma Lucidum Compounds and Synthesis of Derivatives and Probes (SJ-19-0035)
- CDK2 PROTACS for Hearing Loss and Cancer (SJ-20-0021)
- CYP3A4 inhibitors (SJ-24-0036)
- Chloroquine and chloroquine analogs (SJ-02-0008, SJ-05-0017)
- Combination IFN and NEI Therapy for Cancer (SJ-21-0033)
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- Diagnosing and treating learning or mental disorders with SERCA2 protein and miRNAs (SJ-10-0003, SJ-12-0020)
- Drug combination for treating cytokine storms of COVID-19 and other conditions (SJ-21-0008)
- EZHIP(CXorf67)-PRC2 interaction and ependymoma (SJ-17-0030)
- Flouromannitol PET Imaging Agent (SJ-23-0039)
- GNCK1a/CK1alpha degrading compounds (SJ-22-0028, SJ-21-0048)
- GSPT1/2 Degraders (SJ-20-0040)
- Human G1 To S Phase Transition Protein 1 Homolog (GSPT1) Degrader (SJ-21-0001)
- Hybrid compounds to treat gastrointestinal infections (SJ-14-0019/UTA 14-01)
- Improving learning and treating neurological diseases (SJ-15-0009)
- Injectable prodrug of spectinamide as anti-tuberculosis agents (SJ-18-0007)
- JAK PROTAC (SJ-19-0047)
- KDM4B Degraders (SJ-24-0004)
- MAGE-A11 inhibitor for cancer (SJ-20-0033)
- Method for treating COVID-19 (SJ-20-0035)
- NLRP12 Activators and Screening Tool (SJ-23-0016)
- Neurokinin-1 receptor antagonists as antifungal enhancers (SJ-21-0021)
- New JAK PROTACs (SJ-21-0010)
- Novel carboxylesterase inhibitors (SJ-02-0030)
- P27 Inhibitors for Hearing Regeneration and/or Breast Cancer (SJ-18-0016)
- PROTACs for GSPT1 and PXR (SJ-22-0029)
- Preventing and treating hearing loss using CDK2 inhibitors (SJ-14-0028)
- Proteolytic Targeting Chimeras (PROTACs) for Targeting LCK-driven Leukemia (SJ-21-0047)
- Reactive Oxygen Species (ROS) Imaging Agent (SJ-23-0008)
- SARM for Kennedy's disease (SJ-18-0012)
- SPA70 is a potent antagonist of human pregnane X receptor (PXR antagonists) (SJ-16-0011)
- Small molecule modulators of PanK (SJ-18-0046)
- Small molecules that can be used for targeted protein degradation of GSPT1/IKZF1 (SJ-21-0045)
- Specific retinoid receptor agonists and antagonists for cancer (SJ-14-0011)
- Spectinomycin Antibiotics (mSPCs) (SJ-13-0041)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
- Therapeutic leads targeting influenza endonuclease (SJ-09-0041)
- Transcription factors for cochlear hearing loss therapy (SJ-17-0016)
- Treating cochlear hearing loss with p27Kip1/Atoh1 combinations (SJ-13-0019)
- Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- VIPR1 modulators for improving auditory capabilities (SJ-22-0023)
For more information
Contact the Office of Technology Licensing:
Phone: (901) 595-2342
Fax: (901) 595-3148